Correction to: Prevalence of tumour-infiltrating CD103+ cells identifies therapeutic-sensitive prostate cancer with poor clinical outcome

Br J Cancer. 2023 May;128(9):1788-1789. doi: 10.1038/s41416-023-02211-3.
No abstract available

Publication types

  • Published Erratum